GlassScriptPhysician profile
Allen A Alvarez
NPI 1497995484
$3,074.30
in general payments reported to CMS, 2019-2025
37 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $227 · 2021: $595 · 2022: $802 · 2023: $343 · 2024: $521 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176 · Travel and Lodging: $31.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.45 |
| Travel and Lodging | $31.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $588.49 | 2022-2025 | Signia, Sonicision, Endo Gia Ultra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.78 | 2019-2023 | Xifaxan |
| Daiichi Sankyo INC. | $325.80 | 2020-2023 | Injectafer |
| Novo Nordisk INC | $205.17 | 2019-2025 | Wegovy |
| Intuitive Surgical, INC. | $159.86 | 2020-2023 | Da Vinci Surgical System |
| Phathom Pharmaceuticals, INC. | $134.66 | 2024 | Voquezna |
| Lexington Medical, INC. | $110.92 | 2024-2025 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Depuy Synthes Sales INC. | $100.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.58 | 2020-2023 | Gattex |
| Shire North American Group INC | $88.44 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $87.39 | 2024-2025 | |
| Lilly USA, LLC | $82.00 | 2023-2025 | Zepbound, Mounjaro |
| Endo Pharmaceuticals INC. | $79.85 | 2020-2021 | |
| Baxter Healthcare | $71.28 | 2022 | |
| Currax Pharmaceuticals LLC | $54.12 | 2021-2025 | Contrave |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $47.24 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $39.57 | 2021-2025 | Exparel |
| Innocoll Pharmaceuticals Limited | $35.94 | 2021-2022 | |
| Nalpropion Pharmaceuticals LLC | $33.88 | 2019 | |
| Standard Bariatrics, INC. | $29.70 | 2022 | |
| Lsi Solutions INC | $26.51 | 2022 | |
| Acell, INC. | $25.61 | 2019 | |
| Integra Lifesciences Corporation | $22.49 | 2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Stryker Corporation | $20.29 | 2021 | |
| Kerecis Limited | $20.17 | 2020 | |
| Ethicon US, LLC | $19.85 | 2025 | Echelon Flex |
| Trevena, INC. | $18.48 | 2021 | |
| Vivus LLC | $17.85 | 2020 | |
| Medinc of Texas | $17.33 | 2022 | |
| Boston Scientific Corporation | $16.53 | 2025 | Spyglass Discover |
| W. L. Gore & Associates, INC. | $15.60 | 2023 | Seamguard |
| Redhill Biopharma INC. | $15.37 | 2020 | |
| Davol INC. | $14.25 | 2021 | |
| Shield Therapeutics INC | $12.02 | 2022 | |
| Covidien LP | $11.99 | 2019 | |
| Microline Surgical INC | $4.62 | 2025 | |
| Kvk-Tech, INC. | $2.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.